In conclusion, ActRIIA‐mFc and FSTΔHBS‐hFc therapy both showed a potential for reducing primary tumor volume and tumor‐associated bone remodeling alone or in combination with bisphosphonate. Here, ACVR2A is linked to neoplasm.